

Medibio Signs Clinical Trial Agreement With US-based MedBridge Healthcare LLC For its Depressive Burden Trial

Melbourne, Australia and Minneapolis, MN – 7 October 2020: Medibio Limited (“MEB” or “Medibio”)(ASX: MEB)(OTCPINK: MDBIF), a mental health technology company pioneering the use of objective measures to aid in the early detection and screening of certain mental health conditions, is pleased to announce that it has entered into a Clinical Trial Agreement (“CTA”) with MedBridge Healthcare LLC (“MedBridge”), to support Medibio’s Sleep Analysis of Depressive Burden (“SADB”) trial. The SADB trial aims to identify clinical depressive burden in patients with sleep disturbance who undergo a sleep study in a clinical environment.

MedBridge is the leading provider of sleep laboratory management services in the United States, operating over 130 sleep disorder diagnostic centres and performing over 70,000 sleep disorder diagnostic procedures annually. MedBridge partners with hospitals and physician practices to offer comprehensive, fully-integrated services for the identification, testing, diagnosis, therapeutic coordination, and long-term care management of patients with sleep disorders.

Under the CTA, MedBridge, in collaboration with Ohio Sleep Solutions in Columbus, Ohio, will coordinate research guidelines and services for the purposes of the SADB trial to help fast-track patient recruitment.

John Mathias, Chief Development Officer of MedBridge, said, *“As the leading sleep management service provider in the US, we are excited about the potential of Medibio’s technology and its clinical applications. The objective identification of depression in patients that suffer certain sleep disorders is an unmet need and we are pleased to be working with Medibio to fast-track patient recruitment for the SADB trial.”*

Claude Solitario, Managing Director of Medibio Ltd, said, *“We are delighted to have MedBridge as a partner for our Sleep Analysis of Depressive Burden trial. Their expertise and reputation in sleep medicine in the United States is exemplary, and the size of MedBridge’s operations will help ensure that our SADB trial will be undertaken quickly and efficiently. MedBridge’s participation in this collaboration underscores the importance of our endeavour and attests to the quality of our research team.”*

– ENDS –

This announcement is authorised for release to the market by the Board of Directors of Medibio Limited

ASX Announcement

Medibio Limited – 7 October 2020



About Medibio Limited

Medibio (ASX: MEB) (OTCPINK: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTC Pink Open Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.

Medibio Investor and Media Enquiries:

Arthur Chan

WE Communications

T: +61 (0) 404 369 388

WE-AUMedibio@we-worldwide.com

About MedBridge Healthcare

MedBridge Healthcare (the “Company”) is the largest full-service provider of sleep diagnostic testing services in the U.S. The Company’s services support the diagnosis and treatment of Obstructive Sleep Apnea (OSA) and other sleep disorders. The Company primarily operates as an outsourced ancillary services provider, providing sleep lab management services to clients including the Johns Hopkins Health System, various academic facilities, hospital systems and physician groups. The Company manages sleep labs in over 130 locations across 21 states and also owns and operates a network of independent sleep labs. In addition to lab management services and sleep testing services, the company also provides Home Sleep Apnea Testing (HSAT) services via mail order and in-lab pickup. The Company conducts approximately 70,000 sleep studies per year.

MedBridge Healthcare Investor and Media Enquiries:

John Mathias

jmathias@medbridgegroup.com